Vor Biopharma Inc (VOR) Price

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 159 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidates include tremtelectogene empogeditemcel (trem-cel), for the treatment of acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II multicenter, open-label, first-in-human study of trem-cel in patients with AML. Its other clinical trial and pipeline products are VCAR33 / VBP301, Trem-cel+VCAR33 Treatment, System CD33-CLL1 Treatment System, and VADC45.